Hepatitis C Articles (HCV)
Back
	HCV Highlights / EASL       The International Liver Congress™ EASL - European Association for the Study of the Liver Barcelona, Spain 13-17 April 2016   Newest HCV Drugs at EASL - (05/03/16)   ABT-493 + ABT-530 at EASL - (05/03/16)   Sofosbuvir / Velpatasvir.... + GS-9857 - (05/03/16)   Daclatasvir+SOF at EASL 2016 - (05/18/16)   EASL: Resistance Analysis in 1284 Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir in the Phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 Studies - (04/15/16)   EASL: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated With Direct-Acting Antivirals - (04/15/16)   EASL: High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 With or Without Ribavirin for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1 HCV Infection - (04/15/16)   EASL: Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis - (04/21/16)   EASL: EUROPEAN RAVS DATABASE: FREQUENCY AND CHARACTERISTICS OF RAVS IN TREATMENT-NAÏVE AND DAA-EXPERIENCED PATIENTS - (04/29/16)   EASL: Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals - (04/25/16)   Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution - (04/27/16)   Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV - Letter to the Editor - (05/18/16)   High HCV Reinfection Rates Reported in HIV+, MSM (25%), IDUs at EASL: multiple reinfections reported - (05/10/16)   Hep C Articles…   Hep B Articles…   HIV Articles…   Neurodegeneration and Ageing in the HAART Era....... - (05/18/16)           View Older Articles   Back to Top   www.natap.org